Mereo BioPharma
MREO
64 hedge funds and large institutions have $181M invested in Mereo BioPharma in 2023 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 9 closing their positions.
1,970% more call options, than puts
Call options by funds: $2.21M | Put options by funds: $107K
101% more capital invested
Capital invested by funds: $90.4M → $181M (+$91M)
89% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 9
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
14% more funds holding
Funds holding: 56 → 64 (+8)
1.14% more ownership
Funds ownership: 10.06% → 11.2% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$6.16M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.54M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$2.97M |
| 5 |
Alkeon Capital Management
New York
|
+$956K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$3.67M |
| 2 |
JGC
J. Goldman & Co
New York
|
-$542K |
| 3 |
FAM
Formidable Asset Management
Cincinnati,
Ohio
|
-$428K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$351K |
| 5 |
JP Morgan Chase
New York
|
-$217K |
MREO Hedge Fund Activity: Q4 2023 in Review
64 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q4 2023, worth a combined $181M — up 101% from $90.4M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new MREO positions and 9 closed out — a net gain of 8 holders — while 19 added to existing stakes and 13 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $6.16M. The largest seller was Citadel Advisors, cutting an estimated $3.67M.
- 64 institutional investors held Mereo BioPharma (MREO) as of Q4 2023, up from 56 in Q3 2023.
- Funds reported $181M of Mereo BioPharma stock for Q4 2023, up 101% quarter-over-quarter.
- 17 funds opened new Mereo BioPharma positions in Q4 2023 and 9 closed out, a net change of +8 holders.
- The largest Mereo BioPharma buyer in Q4 2023 was Mangrove Partners, an estimated $6.16M added.
- The largest Mereo BioPharma seller in Q4 2023 was Citadel Advisors, an estimated $3.67M sold.
Based on aggregated 13F filings for Q4 2023.